ReviewEuropean respiratory review : an official journal of the European Respiratory Society2010
Revisited role for mucus hypersecretion in the pathogenesis of COPD.
Review in European respiratory review : an official journal of the European Respiratory Society, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Impact of N-Acetylcysteine on Mucus Hypersecretion in the Airways: A Systematic Review.International journal of chronic obstructive pulmonary disease · 2024Pooled it
- Management of airway mucus hypersecretion in chronic airway inflammatory disease: Chinese expert consensus (English edition).International journal of chronic obstructive pulmonary disease · 2018Guideline
- Mucolytic Effectiveness of Tyloxapol in Chronic Obstructive Pulmonary Disease - A Double-Blind, Randomized Controlled Trial.PloS one · 2016Trial
- Precision treatment of COPD based on novel imaging phenotypes: a treatable traits approach.Respiratory research · 2026Review
- Recent Progress in Treating Airway Mucus Hypersecretion by Targeting the Epidermal Growth Factor Receptor Signaling Pathway.Pediatric discovery · 2026Review
- SLC40A1 (iron transporter): mechanistic regulation, role in disease pathogenesis, and prospects for targeted therapy.Frontiers in cell and developmental biology · 2026Review
- The Role of Programmed Cell Death-Related Genes in Asthma, Chronic Obstructive Pulmonary Disease, and Lung Function: A Multi-Omics Mendelian Randomization Study.International journal of chronic obstructive pulmonary disease · 2026Article
- Effective-Component Compatibility of Bufei Yishen Formula (ECC-BYF) III Inhibits Mucus Hypersecretion by BEAS-2B Cells via miR-146a-5p-Mediated Regulation of the EGFR/MEK/ERK Pathway.International journal of chronic obstructive pulmonary disease · 2025Article
- Quantitative adverse outcome pathway modeling for cigarette-smoke-induced airway mucus hypersecretion. Part 1: adverse-outcome-pathway-basedFrontiers in toxicology · 2025Article
- Effects of High Frequency Chest Wall Oscillation (HFCWO) on Clinical Symptoms in Chronic Obstructive Lung Disease.Medical research archives · 2024Article
- Review
- Clinical Efficacy of Carbocysteine in COPD: Beyond the Mucolytic Action.Pharmaceutics · 2022Review
- High miR203a-3p and miR-375 expression in the airways of smokers with and without COPD.Scientific reports · 2022Article
- Article
- Increased Expression ofFrontiers in immunology · 2022Article
- Cytokine Storm and Mucus Hypersecretion in COVID-19: Review of Mechanisms.Journal of inflammation research · 2021Review
- Amelioration of Cigarette Smoke-Induced Mucus Hypersecretion and Viscosity byOxidative medicine and cellular longevity · 2020Article
- Ammonia Exposure Induced Cilia Dysfunction of Nasal Mucosa in the Piglets.BioMed research international · 2020Article
- Nanoparticle diffusion in spontaneously expectorated sputum as a biophysical tool to probe disease severity in COPD.The European respiratory journal · 2019Article
- CD147 increases mucus secretion induced by cigarette smoke in COPD.BMC pulmonary medicine · 2019Article
Corrections and comments
- Commented on by
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic obstructive pulmonary disease (COPD) is a heterogeneous and complex disease of which the basic pathophysiological mechanisms remain largely unknown. On the basis of recent results from pathological studies and large clinical trials, the presence of airway inflammation does not seem to be sufficient to explain the complexity of the disease and the relatively poor response to treatment. It is probably time to abandon the concept of COPD as a unique disease and define, identify and treat the various aspects, which may differ between individuals. Among the different phenotypic distinctions, the classical distinction "chronic bronchitis" has mucus hypersecretion as the key presenting symptom. Its role in COPD has been the subject of an ongoing debate; however, it now appears to be being re-evaluated due to findings from recent epidemiological and pathological studies. In this context, the view that chronic mucus hypersecretion plays a secondary role in the pathogenesis of COPD should be abandoned and instead, drugs targeting mucus hypersecretion should be considered as a treatment option.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.